The annual meeting, held April 16-20 at the Ernest N. Morial Convention Center, will allow AstraZeneca to showcase its oncology portfolio in more than 60 presentations.
“The data we will present at AACR underscore the scientific promise shown by our industry-leading DDR portfolio as well as the clinical potential of this pioneering approach to targeting tumor cells," AstraZeneca VP Andrew Mortlock said. "With three new molecules now in the clinic and one on the market, we are following the science and exploring their potential in both monotherapy and in combination with other therapies.”
Among the presentations will be the results of two clinical trials on DNA Damage Response (DDR) medications. The results of combining Lynparza (olaparib) and AZD5363 in a Phase I study for advanced cancer patients and the initial findings of the Phase Ib study of AZD1775 will be presented to attendees on April 17.
In addition to its research on cancer treatments, AstraZeneca is also developing medications to treat respiratory, inflammation, autoimmune disease (RIA) and cardiovascular and metabolic disease (CVMD).
Alerts Sign-up